Today (5h December 2018) we were delighted to attend the launch of the UK Governments’ second Life Sciences Sector Deal. The deal included major investments totalling £1.3 billion in the UK economy and the launch of a new collaboration between government and industry to drive early disease detection.
Accelerating Detection of Disease will collect data from over 5 million healthy people and use artificial intelligence technologies (AI) to develop the next generation of treatments.
Supporting the work of Medicines Discovery Catapult, highlights also include commitments to:
- Making the UK home to data-driven life science research and innovation
- Develop measures to improve the UK’s health data infrastructure
- Innovative regulation and faster clinical research
Our CEO, Chris Molloy, responds:
“The success of the Life Sciences sector is not only vital to the UK economy but also for the health and wellbeing of the population – we will all be patients one day.
Today’s Life Sciences Sector Deal is an important sign that UK government industry, patients, charities and academia are working together to realise the full potential of our National capability. As a community we are tackling challenges in discovery, through to manufacturing and adoption of new products into the healthcare system.
At the Medicines Discovery Catapult we actively support the Life Sciences Sector Deal and are working hard to broker easier access to consented patient data and samples (Samples & Data), creating connected data, testing new algorithms, AI and machine learning approaches (Informatics), and enabling patient-centred drug discovery through a collective approach to R&D with research charities (Syndicates). We are also industrialising new discovery technologies (Discovery Science & Technology) and enabling access to national UK R&D capabilities (Virtual R&D).”